You are here:
Molecular Pharming: High Level Plant Protein Expression (CPMV-HT) »
The CPMV-HT expression system is already applied industrially. It has been licensed to Medicago Inc. (Quebec, Canada) and several vaccines are currently in clinical trials.
Medicago press releases
QUEBEC CITY - June 30, 2009 - Medicago Inc. (TSX-V: MDG), a biotechnology company focused on developing highly effective and affordable vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced that it has received positive results from an immunogenicity study in mice with the Company's new vaccine candidate for the influenza A (H1N1) virus, also known as swine flu. Results demonstrated that the Company's H1 VLP vaccine induced a positive immune response in mice against the H1N1 influenza virus. Medicago produced the H1 VLP antigen within 14 days of receiving the DNA sequence with its VLP vaccine technology and Proficia™ manufacturing technology.
PBL press releases
Medicago Receives 2009 Genesis Innovation Award - 15 May 2009
CONGRATULATIONS to Prof George Lomonossoff - 28 March 2012
Medicago’s virus-like particle
|©2017 PBL Technology|